These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

728 related articles for article (PubMed ID: 35961700)

  • 1. Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance.
    Ravichandra A; Bhattacharjee S; Affò S
    Adv Cancer Res; 2022; 156():201-226. PubMed ID: 35961700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase.
    Lin Y; Cai Q; Chen Y; Shi T; Liu W; Mao L; Deng B; Ying Z; Gao Y; Luo H; Yang X; Huang X; Shi Y; He R
    Hepatology; 2022 Jan; 75(1):28-42. PubMed ID: 34387870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SERPINE1: Role in Cholangiocarcinoma Progression and a Therapeutic Target in the Desmoplastic Microenvironment.
    Czekay RP; Higgins CE; Aydin HB; Samarakoon R; Subasi NB; Higgins SP; Lee H; Higgins PJ
    Cells; 2024 May; 13(10):. PubMed ID: 38786020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
    Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
    Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
    [No Abstract]   [Full Text] [Related]  

  • 5. Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of
    Li JH; Wu X; Ni X; Li YX; Xu L; Hao XY; Zhao W; Zhu XX; Yin XY
    Clin Transl Med; 2023 Mar; 13(3):e1213. PubMed ID: 36855786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-Associated Fibroblasts in Hepatocellular Carcinoma and Cholangiocarcinoma.
    Ying F; Chan MSM; Lee TKW
    Cell Mol Gastroenterol Hepatol; 2023; 15(4):985-999. PubMed ID: 36708970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HS6ST1 overexpressed in cancer-associated fibroblast and inhibited cholangiocarcinoma progression.
    Hu S; Xia C; Zou H; Ren W; Liu L; Wang L; Kang Q; He K; Wang T; Zhang X
    Dig Liver Dis; 2023 Aug; 55(8):1114-1125. PubMed ID: 36586771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cancer-associated fibroblasts/tumor cells cross-talk inhibits intrahepatic cholangiocarcinoma progression via cell-cycle arrest.
    Mancarella S; Gigante I; Pizzuto E; Serino G; Terzi A; Dituri F; Maiorano E; Vincenti L; De Bellis M; Ardito F; Calvisi DF; Giannelli G
    J Exp Clin Cancer Res; 2024 Oct; 43(1):286. PubMed ID: 39415286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matricellular proteins in intrahepatic cholangiocarcinoma.
    Sirica AE
    Adv Cancer Res; 2022; 156():249-281. PubMed ID: 35961702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-associated fibroblasts promote tumor cell growth via miR-493-5p in intrahepatic cholangiocarcinoma.
    Toshida K; Itoh S; Harada N; Morinaga A; Yugawa K; Tomiyama T; Kosai-Fujimoto Y; Tomino T; Kurihara T; Nagao Y; Morita K; Oda Y; Yoshizumi T
    Cancer Sci; 2023 Mar; 114(3):937-947. PubMed ID: 36369960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations.
    Affo S; Nair A; Brundu F; Ravichandra A; Bhattacharjee S; Matsuda M; Chin L; Filliol A; Wen W; Song X; Decker A; Worley J; Caviglia JM; Yu L; Yin D; Saito Y; Savage T; Wells RG; Mack M; Zender L; Arpaia N; Remotti HE; Rabadan R; Sims P; Leblond AL; Weber A; Riener MO; Stockwell BR; Gaublomme J; Llovet JM; Kalluri R; Michalopoulos GK; Seki E; Sia D; Chen X; Califano A; Schwabe RF
    Cancer Cell; 2021 Jun; 39(6):866-882.e11. PubMed ID: 33930309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition.
    Mancarella S; Gigante I; Serino G; Pizzuto E; Dituri F; Valentini MF; Wang J; Chen X; Armentano R; Calvisi DF; Giannelli G
    J Exp Clin Cancer Res; 2022 Nov; 41(1):331. PubMed ID: 36443822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zinc Finger E-Box Binding Homeobox 1 Promotes Cholangiocarcinoma Progression Through Tumor Dedifferentiation and Tumor-Stroma Paracrine Signaling.
    Lobe C; Vallette M; Arbelaiz A; Gonzalez-Sanchez E; Izquierdo L; Pellat A; Guedj N; Louis C; Paradis V; Banales JM; Coulouarn C; Housset C; Vaquero J; Fouassier L
    Hepatology; 2021 Dec; 74(6):3194-3212. PubMed ID: 34297412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells?
    Wang J; Loeuillard E; Gores GJ; Ilyas SI
    Expert Opin Ther Targets; 2021 Oct; 25(10):835-845. PubMed ID: 34806500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance.
    Dzobo K; Dandara C
    OMICS; 2020 Jun; 24(6):314-339. PubMed ID: 32496970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-Associated Fibroblasts and Extracellular Matrix: Therapeutical Strategies for Modulating the Cholangiocarcinoma Microenvironment.
    Minini M; Fouassier L
    Curr Oncol; 2023 Apr; 30(4):4185-4196. PubMed ID: 37185432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative analyses of bulk and single-cell transcriptomics reveals the infiltration and crosstalk of cancer-associated fibroblasts as a novel predictor for prognosis and microenvironment remodeling in intrahepatic cholangiocarcinoma.
    Zhong YJ; Luo XM; Liu F; He ZQ; Yang SQ; Ma WJ; Wang JK; Dai YS; Zou RQ; Hu YF; Lv TR; Li FY; Hu HJ
    J Transl Med; 2024 May; 22(1):422. PubMed ID: 38702814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-associated fibroblasts: Versatile mediators in remodeling the tumor microenvironment.
    Zhang Q; Wang Y; Liu F
    Cell Signal; 2023 Mar; 103():110567. PubMed ID: 36538999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma.
    Mertens JC; Fingas CD; Christensen JD; Smoot RL; Bronk SF; Werneburg NW; Gustafson MP; Dietz AB; Roberts LR; Sirica AE; Gores GJ
    Cancer Res; 2013 Jan; 73(2):897-907. PubMed ID: 23221385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma.
    Cantallops Vilà P; Ravichandra A; Agirre Lizaso A; Perugorria MJ; Affò S
    Hepatology; 2024 Apr; 79(4):941-958. PubMed ID: 37018128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.